TICKERNERD
Menu
RLMDRLMDHealthcare · Biotechnology

RLMD Stock Forecast: Relmada Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$4.93
−8.19% on the day

The 6 Wall Street analysts covering Relmada Therapeutics, Inc. hold a median 12-month price target of $12 — +143.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 8 Aug 2026 — in the upper half.

Market cap
$518.6M
Ticker Nerd rank
69 / 100
Median analyst target
$12
Analysts covering
6
Total return, dividends reinvested
1W
−7.2%
1M
−23.1%
YTD
+2.1%
1Y
+718.9%
From 52W high
−37.3%
From 52W low
+775.7%
$0.56
$7.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RLMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Relmada Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Revisions
73
Quality
64
Value
63
Growth
55
Size
53
Accruals
44
Volatility
38
Issuance
27

Momentum (96): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Relmada Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

RLMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26RLMDHigh $19Median $12Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $9Median $12High $19

The green dot is the last close — the median target sits +143.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 June 2026HC Wainwright & Co.InitiatesBuy$12
24 Mar 2026Piper SandlerInitiatesOverweight—
20 Mar 2026MizuhoMaintainsOutperform—
2 Mar 2026LUCID CAPITAL MARKETSInitiatesBuy—
23 Jan 2026Leerink PartnersUpgradeOutperform—
22 Dec 2025JefferiesInitiatesBuy—
19 Nov 2025MizuhoUpgradeOutperform—
5 Dec 2024MizuhoDowngradeNeutral—
4 Dec 2024Leerink PartnersDowngradeMarket Perform—
17 Sept 2024JefferiesUpgradeBuy$3.50 → $13
5 June 2024Goldman SachsDowngradeSell—
15 June 2023MizuhoReiteratesBuy—
23 Jan 2023SVB LeerinkMaintainsOutperform—
14 Oct 2022Goldman SachsDowngradeNeutral—
14 Oct 2022GuggenheimDowngradeNeutral—
13 Oct 2022OppenheimerDowngradePerform—
23 Sept 2022Goldman SachsMaintainsBuy—
6 Sept 2022GuggenheimMaintainsBuy—
9 May 2022OppenheimerMaintainsOutperform—
24 Mar 2022Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

RLMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Relmada Therapeutics, Inc. (RLMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.4×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
4.3×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 33% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−25.6%

Higher than 29% of US stocks

Return on assets
−14.4%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RLMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLMDRelmada Therapeutics, Inc.$518.6M
69
DNAGinkgo Bioworks Holdings, Inc.$516.2M
49
ASMBAssembly Biosciences, Inc.$528.7M
89
EVMNEvommune, Inc.$507.1M
10
MPLTMapLight Therapeutics, Inc.$531.1M
5
TENXTenax Therapeutics, Inc.$503.0M
50
EIKNEikon Therapeutics, Inc.$502.6M
1
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest RLMD news & analysis

Relmada Therapeutics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Relmada Therapeutics, in its second-quarter earnings call, said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, targeting an investigational new drug application filing by the end of 2026.

Why it matters — The update outlines the company's near-term development timeline for its NDV-01 pipeline program, giving RLMD watchers clarity on its manufacturing priorities and planned regulatory milestone.

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Relmada Therapeutics held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational updates for the second quarter of 2026.

Why it matters — The earnings call transcript provides investors and analysts with management's commentary on the company's quarterly performance and business outlook.

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

GlobeNewsWire · 28 July 2026positive

Relmada Therapeutics appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer to lead its corporate strategy, commercial planning, and business development activities. He will report directly to CEO Sergio Traversa.

Why it matters — The appointment of a uro-oncology leader to a senior executive role adds relevant industry experience to Relmada's management team during its clinical-stage development.

FAQ

Frequently asked questions about RLMD stock

What is the RLMD stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Relmada Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $9 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RLMD stock a buy right now?

Of the 6 analysts covering Relmada Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relmada Therapeutics, Inc. 69 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLMD?

As at 8 Aug 2026, Relmada Therapeutics, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will RLMD stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +143.4% from the last close, and Ticker Nerd's factor model ranks Relmada Therapeutics, Inc. 69 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RLMD stock forecast for 2030?

No analyst covering Relmada Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $19 over the next 12 months.

How has RLMD stock performed over the past year?

Relmada Therapeutics, Inc. returned +718.9% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Relmada Therapeutics, Inc. do?

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system disorders and oncology indications.

What is the latest news on RLMD?

The most recent item we track (MarketBeat, 7 Aug 2026): "Relmada Therapeutics Q2 Earnings Call Highlights". Relmada Therapeutics, in its second-quarter earnings call, said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, targeting an investigational new drug application filing by the end of 2026.

Company

About Relmada Therapeutics, Inc.

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system disorders and oncology indications. Its primary efforts center on NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel designed for the treatment of non-muscle invasive bladder cancer, particularly in high-risk BCG-unresponsive and intermediate-risk patients, addressing significant unmet needs in urologic oncology. The company is also advancing programs in CNS diseases, including esmethadone (REL-1017), an N-methyl-D-aspartate receptor antagonist serving as an oral agent for depression, and sepranolone, a GABAA-modulating compound targeted at compulsivity-related disorders such as Prader-Willi syndrome. Relmada Therapeutics Inc. operates within the biotechnology sector, emphasizing chemical entities and innovative drug delivery systems to improve patient outcomes in areas with limited treatment options. Headquartered in Coral Gables, Florida, and founded in 2012, the company remains committed to advancing its pipeline through clinical development and regulatory interactions in the healthcare market.

CEO Dr. Sergio Traversa M.B.A., Pharm.D. · 17 employees · United States · https://www.relmada.com